Bank of America Cuts West Pharmaceutical Price Target 19% to $300; Board Declares $0.22 Dividend and $1B Buyback
Bank of America lowered West Pharmaceutical’s price target by 19% to $300 from $370 following FY26 guidance above expectations and sector-wide multiple compression. The Board also declared a $0.22 quarterly dividend payable May 6 and approved a $1 billion share repurchase program.
1. Analyst Price-Target Revision
On February 13, Bank of America reduced West Pharmaceutical’s price target from $370 to $300, maintaining a Buy rating after incorporating FY26 guidance that exceeded expectations and accounting for broader sector multiple compression.
2. Quarterly Dividend Declaration
On February 16, West Pharmaceutical’s Board declared a regular quarterly dividend of $0.22 per share, payable on May 6, 2026, to shareholders of record as of April 29, 2026, reflecting the company’s ongoing capital return policy.
3. $1 Billion Share Repurchase Authorization
On February 17, the Board authorized a new share repurchase program of up to $1 billion of common stock, aimed at enhancing shareholder value through disciplined capital allocation.
4. Company Profile and Growth Drivers
West Pharmaceutical supplies specialized components for injectable drug delivery and reported accelerating growth in its non-GLP-1 high-value products segment, supporting its solid year-end performance and robust FY26 outlook.